{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T06:26:15Z","timestamp":1787293575471,"version":"build-2736575974"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T00:00:00Z","timestamp":1779753600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T00:00:00Z","timestamp":1779753600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100019084","name":"Kobe University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100019084","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Endocrinol Invest"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>\n                      Anti-PIT-1 hypophysitis is a rare T cell-mediated autoimmune pituitary disorder presenting as a paraneoplastic syndrome or after immune checkpoint inhibitor (ICI) therapy, and its predominance in Japan suggests an underlying genetic predisposition. The NLR family CARD domain containing 5 (\n                      <jats:italic>NLRC5<\/jats:italic>\n                      ) encodes a key transcriptional regulator of major histocompatibility complex (MHC) class I, and its p.Pro191Leu missense variant is associated with ICI-related endocrinopathies and enhanced interferon-\u03b3 responses. Therefore, we examined whether NLRC5 p.Pro191Leu is enriched in anti-PIT-1 hypophysitis.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      We genotyped the NLRC5 p.Pro191Leu variant (c.572\u00a0C\u2009&gt;\u2009T) in seven Japanese individuals with anti-PIT-1 hypophysitis for whom genomic DNA was available. The carrier frequency observed in this cohort was compared with ancestry-matched expectations from the Tohoku Medical Megabank 61KJPN Japanese reference panel using a prespecified one-sided exact binomial test. Sensitivity analyses included Mid-\n                      <jats:italic>P<\/jats:italic>\n                      adjustment, risk differences, and risk ratios.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Among seven genotyped Japanese individuals with anti-PIT-1 hypophysitis, five (71.4%) were carriers, exceeding the expected ancestry-matched frequency from the Japanese reference panel (expected carrier frequency 37.7%; exact\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.076; mid-\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.045). The effect sizes were risk difference\u2009+\u20090.337 and risk ratio 1.89.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This study provides suggestive evidence that the NLRC5 p.Pro191Leu variant may confer genetic susceptibility to anti-PIT-1 hypophysitis in the Japanese population, based on its enrichment relative to ancestry-matched reference panels. These findings, together with NLRC5\u2019s role as the master regulator of MHC class I expression, propose a novel and testable pathogenic model.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s40618-026-02926-z","type":"journal-article","created":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T10:43:25Z","timestamp":1779792205000},"page":"2571-2576","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["NLRC5 p.Pro191Leu as a genetic susceptibility factor in anti-PIT-1 hypophysitis"],"prefix":"10.1007","volume":"49","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7996-232X","authenticated-orcid":false,"given":"Shin","family":"Urai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7421-2714","authenticated-orcid":false,"given":"Hironori","family":"Bando","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7000-8134","authenticated-orcid":false,"given":"Masaaki","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8810-0230","authenticated-orcid":false,"given":"Genzo","family":"Iguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1337-9246","authenticated-orcid":false,"given":"Yutaka","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,26]]},"reference":[{"key":"2926_CR1","doi-asserted-by":"publisher","first-page":"K1","DOI":"10.1093\/ejendo\/lvad179","volume":"190","author":"S Urai","year":"2024","unstructured":"Urai S, Iguchi G, Kanie K et al (2024) Clinical features of anti-pituitary-specific transcription factor-1 (PIT-1) hypophysitis: a new aspect of paraneoplastic autoimmune condition. Eur J Endocrinol 190:K1\u2013K7. https:\/\/doi.org\/10.1093\/ejendo\/lvad179","journal-title":"Eur J Endocrinol"},{"key":"2926_CR2","doi-asserted-by":"publisher","first-page":"7900","DOI":"10.1038\/s41467-025-63183-x","volume":"16","author":"K Kanie","year":"2025","unstructured":"Kanie K, Ito T, Iguchi G et al (2025) Modeling of T cell-mediated autoimmune pituitary disease using human induced pluripotent stem cell-originated organoid. Nat Commun 16:7900. https:\/\/doi.org\/10.1038\/s41467-025-63183-x","journal-title":"Nat Commun"},{"key":"2926_CR3","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1507\/endocrj.EJ25-0035","volume":"72","author":"H Bando","year":"2025","unstructured":"Bando H, Urai S, Kanie K, Yamamoto M (2025) Hypopituitarism: genetic, developmental, and acquired etiologies with a focus on the emerging concept of autoimmune hypophysitis. Endocr J 72:649\u2013662. https:\/\/doi.org\/10.1507\/endocrj.EJ25-0035","journal-title":"Endocr J"},{"key":"2926_CR4","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1038\/s41574-025-01099-8","volume":"21","author":"S Urai","year":"2025","unstructured":"Urai S, Iguchi G, Takahashi Y (2025) Anti-PIT1 hypophysitis after immune checkpoint inhibitor treatment. Nat Rev Endocrinol 21:265\u2013266. https:\/\/doi.org\/10.1038\/s41574-025-01099-8","journal-title":"Nat Rev Endocrinol"},{"key":"2926_CR5","doi-asserted-by":"publisher","first-page":"e006570","DOI":"10.1136\/jitc-2022-006570","volume":"11","author":"JI Caulfield","year":"2023","unstructured":"Caulfield JI, Aizenbud L, Perdigoto AL et al (2023) Germline genetic variants are associated with development of insulin-dependent diabetes in cancer patients treated with immune checkpoint inhibitors. J Immunother Cancer 11:e006570. https:\/\/doi.org\/10.1136\/jitc-2022-006570","journal-title":"J Immunother Cancer"},{"key":"2926_CR6","doi-asserted-by":"publisher","unstructured":"Aizenbud L, Savion Gaiger N, Perdigoto AL et al (2025) Factors that increase class I MHC expression may contribute to the development of immune checkpoint inhibitor-induced diabetes. J Immunother Cancer 13. https:\/\/doi.org\/10.1136\/jitc-2025-012358","DOI":"10.1136\/jitc-2025-012358"},{"key":"2926_CR7","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1038\/nri3339","volume":"12","author":"KS van den Kobayashi","year":"2012","unstructured":"van den Kobayashi KS (2012) NLRC5: a key regulator of MHC class I-dependent immune responses. Nat Rev Immunol 12:813\u2013820. https:\/\/doi.org\/10.1038\/nri3339","journal-title":"Nat Rev Immunol"},{"key":"2926_CR8","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.trecan.2016.12.003","volume":"3","author":"S Yoshihama","year":"2017","unstructured":"Yoshihama S, Vijayan S, Sidiq T, Kobayashi KS (2017) NLRC5\/CITA: A key player in cancer immune surveillance. Trends Cancer 3:28\u201338. https:\/\/doi.org\/10.1016\/j.trecan.2016.12.003","journal-title":"Trends Cancer"},{"key":"2926_CR9","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1111\/imm.13235","volume":"162","author":"SX Cho","year":"2021","unstructured":"Cho SX, Vijayan S, Yoo J-S et al (2021) MHC class I transactivator NLRC5 in host immunity, cancer and beyond. Immunology 162:252\u2013261. https:\/\/doi.org\/10.1111\/imm.13235","journal-title":"Immunology"},{"key":"2926_CR10","doi-asserted-by":"publisher","first-page":"e13395","DOI":"10.1111\/jne.13395","volume":"36","author":"S Urai","year":"2024","unstructured":"Urai S, Tomofuji S, Bando H et al (2024) The early-stage clinical course of anti-pituitary-specific transcription factor-1 hypophysitis diagnosed post-immune checkpoint inhibitor treatment: A case with review of literature. J Neuroendocrinol 36:e13395. https:\/\/doi.org\/10.1111\/jne.13395","journal-title":"J Neuroendocrinol"},{"key":"2926_CR11","unstructured":"Japanese Multi Omics Reference Panel https:\/\/ https:\/\/jmorp.megabank.tohoku.ac.jp\/genome-variations\/sr-snvindel\/081b311f588b80000. Accessed 11 Nov 2025"},{"key":"2926_CR12","unstructured":"Togo Var https:\/\/grch38.togovar.org\/variant\/tgv55625754. Accessed 11 Nov 2025"},{"key":"2926_CR13","unstructured":"gnomAD v4 https:\/\/gnomad.broadinstitute.org\/. Accessed 14 Nov 2025"},{"key":"2926_CR14","unstructured":"The Genotype-Tissue Expression (GTEx) Portal. https:\/\/www.gtexportal.org\/home\/. Accessed 11 Nov 2025"},{"key":"2926_CR15","unstructured":"Polymorphism Phenotyping v2 http:\/\/genetics.bwh.harvard.edu\/pph2\/. Accessed 7 Nov 2025"},{"key":"2926_CR16","unstructured":"Sorting Intolerant From Tolerated https:\/\/sift.bii.a-star.edu.sg\/. Accessed 7 Nov 2025"},{"key":"2926_CR17","unstructured":"MutationTaster https:\/\/www.genecascade.org\/MutationTaster2025\/. Accessed 7 Nov 2025"},{"key":"2926_CR18","unstructured":"Align\u2013Grantham Variation Grantham Deviation http:\/\/agvgd.hci.utah.edu\/agvgd_input.php. Accessed 7 Nov 2025"},{"key":"2926_CR19","unstructured":"SpliceAI https:\/ https:\/\/spliceailookup.broadinstitute.org\/. Accessed 7 Nov 2025"},{"key":"2926_CR20","unstructured":"Combined Annotation Dependent Depletion https:\/\/cadd.gs.washington.edu\/. Accessed 7 Nov 2025"},{"key":"2926_CR21","unstructured":"eQTLGen I https:\/\/www.eqtlgen.org\/phase1.html. Accessed 7 Nov 2025"},{"key":"2926_CR22","unstructured":"NIH LDlink https:\/\/ldlink.nih.gov\/?tab=home. Accessed 7 Nov 2025"},{"key":"2926_CR23","doi-asserted-by":"publisher","first-page":"5999","DOI":"10.1073\/pnas.1602069113","volume":"113","author":"S Yoshihama","year":"2016","unstructured":"Yoshihama S, Roszik J, Downs I et al (2016) NLRC5\/MHC class I transactivator is a target for immune evasion in cancer. Proc Natl Acad Sci U S A 113:5999\u20136004. https:\/\/doi.org\/10.1073\/pnas.1602069113","journal-title":"Proc Natl Acad Sci U S A"}],"container-title":["Journal of Endocrinological Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40618-026-02926-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40618-026-02926-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40618-026-02926-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T06:08:49Z","timestamp":1787292529000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40618-026-02926-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,26]]},"references-count":23,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2026,9]]}},"alternative-id":["2926"],"URL":"https:\/\/doi.org\/10.1007\/s40618-026-02926-z","relation":{},"ISSN":["1720-8386"],"issn-type":[{"value":"1720-8386","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,26]]},"assertion":[{"value":"15 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests relevant to the content of this article.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was conducted in accordance with the Declaration of Helsinki and approved by the Ethics Committee of Kobe University Graduate School of Medicine (approval no.1685). All methods were performed in accordance with the approved protocol guidelines.","order":2,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Written informed consent was obtained from all participants. All participants consented to the submission of the manuscript.","order":3,"name":"Ethics","label":"Consent","group":{"name":"EthicsHeading","label":"Declarations"}}]}}